Parkinson's disease (PD)

Parkinson's disease and clinical studies

Parkinson’s disease (PD) affects ~1-2% of the population above the age of 65 and its prevalence increases dramatically as the population ages. Available treatments are purely symptomatic and have no effect on disease progression. Thus, patients confront a future of progressive disability, early institutionalization and premature death. Neuro-SysMed are running several clinical studies aiming for improved treatment of this disease.

PD has a devastating global socioeconomic impact. In Europe alone, PD affects an estimated 1.2 million people and has a cost of €14 billion per year. Since demographic studies show that patient numbers will continue to grow, effectively doubling by 2040, our failure to make any significant impact to halt or delay disease progression means that PD is now a major challenge to health care and society.

Aims

Advance the mechanistic understanding of PD so that new therapeutic targets can be developed
Address the disorder’s vast clinical and biological heterogeneity and develop biomarkers enabling patient stratification for tailored therapies
Develop and test novel therapies targeting specific molecular pathways

Current clinical trials for PD in Bergen

Completed clinical trials for PD in Bergen (page under construction)

NAD-PARK: Nikotinamide therapy for Parkinson's disease
Park-Ome
Nedsatt mitokondrie-homeostase som ein cellemodell for nevrodegenerasjon